Mark Tepper, PhD (@marktepper) 's Twitter Profile
Mark Tepper, PhD

@marktepper

Serial entrepreneur & founder of multiple biotechs: $RXii, NKTRx, Primatope, JBTRx, $CRBP, EumentisTx. Tweets are my own

ID: 21421580

calendar_today20-02-2009 18:49:20

2,2K Tweet

1,1K Followers

347 Following

Nate Tepper (@natetepper) 's Twitter Profile Photo

We hit 100,000+ downloads for Humans Anonymous in our first two months. We’re building anonymous audio spaces for mental health. The app is popular with teens. It’s clearly meeting a need with younger generations. Here are some early stats 🧵👇

Nate Tepper (@natetepper) 's Twitter Profile Photo

Our mission is to help every human in the world feel less alone. You can download Humans Anonymous here on the App Store here: apple.co/3QjhFQU

Adam Besvinick (@besvinick) 's Twitter Profile Photo

Nate is one of the deepest product thinkers that Looking Glass Capital has been privileged to support — the team and he are building a very meaningful product and community and bringing on a couple engineers to help it scale. DM him or me if you're interested!

BowTiedBiotech 🧪🔬🧬 (@bowtiedbiotech) 's Twitter Profile Photo

😎Friendly reminder: biopharma is NOT excessively profiting vs other industry, in fact operating margins are look to be inline with industry averages. 10 Provocative Realities: 1. Making medicine requires investment capital which is agnostic to industry - no return, no

😎Friendly reminder: biopharma is NOT excessively profiting vs other industry, in fact operating margins are look to be inline with industry averages.

10 Provocative Realities:

1. Making medicine requires investment capital which is agnostic to industry - no return, no
Andrew Pannu (@andrewpannu) 's Twitter Profile Photo

A deep dive into neuropsychiatric therapeutics • Competitive landscape • Emerging treatments • Key concerns & more Exhibit 1: late-stage competitive landscape across key indications The global disease burden for these indications is immense, with >50M total patients &

A deep dive into neuropsychiatric therapeutics

• Competitive landscape
• Emerging treatments
• Key concerns
& more

Exhibit 1: late-stage competitive landscape across key indications

The global disease burden for these indications is immense, with >50M total patients &
Nate Tepper (@natetepper) 's Twitter Profile Photo

I’m interested in having convos with founders whose startups had near death experiences and then survived and went on to be successful. Maybe I’ll record the convos. Feel like those moments aren’t documented enough. A lot to be learned. Who should I talk to?

Mark Tepper, PhD (@marktepper) 's Twitter Profile Photo

PureTech made millions on Karuna acquisition and dividends $100M to shareholders. Bravo! but does this business model work? MC $788M, 27M shares outstanding. By my calculation that's a one time dividend~$3/share. bizjournals.com/boston/news/20… via Boston Business Journal

Mark Tepper, PhD (@marktepper) 's Twitter Profile Photo

EuMentis Therapeutics’ Chief Medical Office Randall Marshall, MD to Give Keynote Presentation at Autism Parenting Summit bit.ly/4dIoJmI

Nate Tepper (@natetepper) 's Twitter Profile Photo

Excited to announce Mentors on Humans Anonymous! In our first week we already have 300+ paying members matched with a real human mentor. Here’s how my own experience having a sponsor in Alcoholics Anonymous inspired this 🧵👇

Excited to announce Mentors on Humans Anonymous!

In our first week we already have 300+ paying members matched with a real human mentor.

Here’s how my own experience having a sponsor in Alcoholics Anonymous inspired this 🧵👇
Mark Tepper, PhD (@marktepper) 's Twitter Profile Photo

EuMentis Therapeutics’ CMO Randall Marshall to Present on its novel PDE10A inhibitor for Tourette Syndrome at TicCon24 einpresswire.com/article/711760… via صحيفة عين الأخبار

Mark Tepper, PhD (@marktepper) 's Twitter Profile Photo

The dangerous rise in antisemitism since October 7 cannot be ignored. Decisive action is required to fight anti-Jewish hate and preserve our democracy. Join American Jewish Committee and urge Congress to act now! actnow.ajc.org/BHcQB7f

Mark Tepper, PhD (@marktepper) 's Twitter Profile Photo

Good news for Lilly but Lilly could have solved this themselves by reducing the price of Zepbound by 50% for dialed higher doses. If they really care about patients they should do this immediately!